A031902 (CASPAR), A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the usual treatment (enzalutamide) alone to using rucaparib plus the usual treatment. The addition of rucaparib to the usual treatment could make patients live longer, or prevent cancer from growing or spreading for a longer time, or both.